Skip to main content
PMC home page
Journal of Medical Ethics logoLink to Journal of Medical Ethics
. 1996 Jun;22(3):140–146. doi: 10.1136/jme.22.3.140

Placebos in clinical practice and research.

P P De Deyn 1, R D'Hooge 1
PMCID: PMC1376977  PMID: 8798935

Abstract

The main current application of placebo is in clinical research. The term placebo effect refers to diverse non-specific, desired or non-desired effects of substances or procedures and interactions between patient and therapist. Unpredictability of the placebo effect necessitates placebo-controlled designs for most trials. Therapeutic and diagnostic use of placebo is ethically acceptable only in few well-defined cases. While "therapeutic" application of placebo almost invariably implies deception, this is not the case for its use in research. Conflicts may exist between the therapist's Hippocratic and scientific obligations. The authors provide examples in neuropsychiatry, illustrating that objective scientific data and well-considered guidelines may solve the ethical dilemma. Placebo control might even be considered an ethical obligation but some provisos should be kept in mind: (a) no adequate therapy for the disease should exist and/or (presumed) active therapy should have serious side-effects; (b) placebo treatment should not last too long; (c) placebo treatment should not inflict unacceptable risks, and (d) the experimental subject should be adequately informed and informed consent given.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BATTEZZATI M., TAGLIAFERRO A., DE MARCHI G. La legatura delle due arterie mammarie interne nei disturbi di vascolarizzazione del miocardio; nota preventiva relativa ai primi dati sperimentali e clinici. Minerva Med. 1955 Oct 31;46(87):1178–1188. [PubMed] [Google Scholar]
  2. BRILL I. C., ROSENBAUM W. M., ROSENBAUM E. E., FLANERY J. R. Internal mammary ligation. Northwest Med. 1958 Apr;57(4):483–486. [PubMed] [Google Scholar]
  3. Beghi E., Tognoni G. Prognosis of epilepsy in newly referred patients: a multicenter prospective study. Collaborative Group for the Study of Epilepsy. Epilepsia. 1988 May-Jun;29(3):236–243. doi: 10.1111/j.1528-1157.1988.tb03712.x. [DOI] [PubMed] [Google Scholar]
  4. Bourgeois B., Leppik I. E., Sackellares J. C., Laxer K., Lesser R., Messenheimer J. A., Kramer L. D., Kamin M., Rosenberg A. Felbamate: a double-blind controlled trial in patients undergoing presurgical evaluation of partial seizures. Neurology. 1993 Apr;43(4):693–696. doi: 10.1212/wnl.43.4.693. [DOI] [PubMed] [Google Scholar]
  5. Brewin T. B. Consent to randomised treatment. Lancet. 1982 Oct 23;2(8304):919–921. doi: 10.1016/s0140-6736(82)90877-7. [DOI] [PubMed] [Google Scholar]
  6. Brown W. A. Placebo as a treatment for depression. Neuropsychopharmacology. 1994 Jul;10(4):265–288. doi: 10.1038/npp.1994.53. [DOI] [PubMed] [Google Scholar]
  7. Brown W. A. Predictors of placebo response in depression. Psychopharmacol Bull. 1988;24(1):14–17. [PubMed] [Google Scholar]
  8. COBB L. A., THOMAS G. I., DILLARD D. H., MERENDINO K. A., BRUCE R. A. An evaluation of internal-mammary-artery ligation by a double-blind technic. N Engl J Med. 1959 May 28;260(22):1115–1118. doi: 10.1056/NEJM195905282602204. [DOI] [PubMed] [Google Scholar]
  9. Curson D. A., Hirsch S. R., Platt S. D., Bamber R. W., Barnes T. R. Does short term placebo treatment of chronic schizophrenia produce long term harm? Br Med J (Clin Res Ed) 1986 Sep 20;293(6549):726–728. doi: 10.1136/bmj.293.6549.726. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. ELLIS L. B., BLUMGART H. L., HARKEN D. E., SISE H. S., STARE F. J. Long-term management of patients with coronary artery disease. Circulation. 1958 May;17(5):945–952. doi: 10.1161/01.cir.17.5.945. [DOI] [PubMed] [Google Scholar]
  11. Elwes R. D., Johnson A. L., Reynolds E. H. The course of untreated epilepsy. BMJ. 1988 Oct 15;297(6654):948–950. doi: 10.1136/bmj.297.6654.948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Goodwin J. S., Goodwin J. M., Vogel A. V. Knowledge and use of placebos by house officers and nurses. Ann Intern Med. 1979 Jul;91(1):106–110. doi: 10.7326/0003-4819-91-1-106. [DOI] [PubMed] [Google Scholar]
  13. KITCHELL J. R., GLOVER R. P., KYLE R. H. Bilateral internal mammary artery ligation for angina pectoris; preliminary clinical considerations. Am J Cardiol. 1958 Jan;1(1):46–50. doi: 10.1016/0002-9149(58)90074-2. [DOI] [PubMed] [Google Scholar]
  14. Kimbel K. H. Ginkgo biloba. Lancet. 1992 Dec 12;340(8833):1474–1474. doi: 10.1016/0140-6736(92)92668-6. [DOI] [PubMed] [Google Scholar]
  15. Kleijnen J., Knipschild P. Ginkgo biloba. Lancet. 1992 Nov 7;340(8828):1136–1139. doi: 10.1016/0140-6736(92)93158-j. [DOI] [PubMed] [Google Scholar]
  16. Knapp M. J., Knopman D. S., Solomon P. R., Pendlebury W. W., Davis C. S., Gracon S. I. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA. 1994 Apr 6;271(13):985–991. [PubMed] [Google Scholar]
  17. LASAGNA L., MOSTELLER F., VON FELSINGER J. M., BEECHER H. K. A study of the placebo response. Am J Med. 1954 Jun;16(6):770–779. doi: 10.1016/0002-9343(54)90441-6. [DOI] [PubMed] [Google Scholar]
  18. Leber P. Is there an alternative to the randomized controlled trial? Psychopharmacol Bull. 1991;27(1):3–8. [PubMed] [Google Scholar]
  19. Levine R. J. The apparent incompatibility between informed consent and placebo-controlled clinical trials. Clin Pharmacol Ther. 1987 Sep;42(3):247–249. doi: 10.1038/clpt.1987.141. [DOI] [PubMed] [Google Scholar]
  20. PARK L. C., COVI L. NONBLIND PLACEBO TRIAL: AN EXPLORATION OF NEUROTIC PATIENTS' RESPONSES TO PLACEBO WHEN ITS INERT CONTENT IS DISCLOSED. Arch Gen Psychiatry. 1965 Apr;12:36–45. [PubMed] [Google Scholar]
  21. Pledger G. W., Kramer L. D. Clinical trials of investigational antiepileptic drugs: monotherapy designs. Epilepsia. 1991 Sep-Oct;32(5):716–721. doi: 10.1111/j.1528-1157.1991.tb04715.x. [DOI] [PubMed] [Google Scholar]
  22. Quitkin F. M., Rabkin J. G., Stewart J. W., McGrath P. J., Harrison W., Ross D. C., Tricamo E., Fleiss J., Markowitz J., Klein D. F. Heterogeneity of clinical response during placebo treatment. Am J Psychiatry. 1991 Feb;148(2):193–196. doi: 10.1176/ajp.148.2.193. [DOI] [PubMed] [Google Scholar]
  23. Reynolds E. H. The influence of antiepileptic drugs on the natural history of epilepsy. Epilepsy Res Suppl. 1991;3:15–20. [PubMed] [Google Scholar]
  24. SHAPIRO A. K. FACTORS CONTRIBUTING TO THE PLACEBO EFFECT. THEIR IMPLICATIONS FOR PSYCHOTHERAPY. Am J Psychother. 1964 Mar;18:SUPPL 1–1:88. doi: 10.1176/appi.psychotherapy.1964.18.s1.73. [DOI] [PubMed] [Google Scholar]
  25. Schönhöfer P. S. Ginkgo biloba extracts. Lancet. 1990 Mar 31;335(8692):788–788. doi: 10.1016/0140-6736(90)90900-p. [DOI] [PubMed] [Google Scholar]
  26. Theodore W. H., Raubertas R. F., Porter R. J., Nice F., Devinsky O., Reeves P., Bromfield E., Ito B., Balish M. Felbamate: a clinical trial for complex partial seizures. Epilepsia. 1991 May-Jun;32(3):392–397. doi: 10.1111/j.1528-1157.1991.tb04668.x. [DOI] [PubMed] [Google Scholar]
  27. Watkins P. B., Zimmerman H. J., Knapp M. J., Gracon S. I., Lewis K. W. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA. 1994 Apr 6;271(13):992–998. [PubMed] [Google Scholar]

Articles from Journal of Medical Ethics are provided here courtesy of BMJ Publishing Group

RESOURCES